AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Hayward, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The firm's portfolio includes DSUVIA, DZUVEO, Zalviso, ARX-02 and ARX-03. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in San Mateo, CA.

AcelRx Pharmaceuticals: Moving Closer To An Attractive Risk-Reward

HAYWARD, Calif., May 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an investigator-initiated study to be conducted at Tampa General Hospital to evaluate the use of DSUVIA for patients with sickle cell disease presenting to the emergency department (ED) with painful vaso-occlusive crisis (VOC).

AcelRx Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease

Agenus

Onconova Therapeutics

Biotech penny stocks continue to heat up; here's 4 under $5 to look into The post Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5

AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2021 Results - Earnings Call Transcript

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 60.00% year over year to ($0.08), which were in line with the estimate of ($0.08).

AcelRx Pharmaceuticals: Q1 Earnings Insights

HAYWARD, Calif., May 17, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its first quarter 2021 financial results.

AcelRx Pharmaceuticals Reports First Quarter 2021 Financial Results

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced a poster presentation at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting reviewing the results of a study on the intraoperative administration of Dsuvia (sufentanil sublingual tablet, SST) 30 mcg for the management of acute pain in an ambulatory surgery center. The primary objective of this study was to determine if SST 30 mcg given before emergence from anesthesia was efficacious in reducing initial post-anesthesia care unit pain scores compared to a control group.

AcelRx's Dsuvia Shows Reduction In Postoperative Opioids Compared To Control Group

HAYWARD, Calif., May 13, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx),  a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in a medically supervised setting, today announced a poster presentation at the 46th Annual Regional Anesthesiology and Acute Pain Medicine Meeting reviewing the results of a study on the intraoperative administration of DSUVIA (sufentanil sublingual tablet; SST) 30 mcg for the management of acute pain in an ambulatory surgery center.

Study of DSUVIA® Showing Significant Reduction in Postoperative Opioids and Better OBAS Scores Compared to Control Group to be Presented at the American Society of Regional Anesthesia (ASRA) Annual Meeting

HAYWARD, Calif., May 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Monday, May 17, 2021.

AcelRx to Host First Quarter 2021 Financial Results Call and Webcast on May 17, 2021

HAYWARD, Calif., May 6, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced an investigator-initiated study to be conducted at The CORE Institute Specialty Hospital in Phoenix, Arizona by the Musculoskeletal Orthopedic Research and Education (MORE) Foundation evaluating the perioperative use of DSUVIA (sufentanil sublingual tablet 30 mcg) for patients undergoing hip or knee replacement as a same-day surgical procedure.

AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or chronic pain management. The study will evaluate the efficacy and safety of Dsuvia for perioperative management of surgical pain in patients on buprenorphine treatment.

AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical Procedure

REDWOOD CITY, Calif., April 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an investigator-initiated study at Montefiore Medical Center evaluating the perioperative use of DSUVIA (sufentanil sublingual tablet 30 mcg) for same-day surgical procedures in patients on buprenorphine therapy for opioid-use disorder or for chronic pain management.

AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure

REDWOOD CITY, Calif., March 31, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Marina Bozilenko as an independent member of the company's Board of Directors.

AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors

REDWOOD CITY, Calif., March 25, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of a pooled analysis of Phase 3 data on the use of DSUVIA for acute pain management in the postoperative and emergency department settings in the Journal of Pain Research.

AcelRx Pharmaceuticals Announces Clinical Data Reporting High Ratings for Healthcare Professional and Patient Satisfaction Following Use of DSUVIA® for Acute Pain in Hospital Settings

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether AcelRx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)

AcelRx Pharmaceuticals, Inc. (ACRX) Management on Q4 2020 Results - Earnings Call Transcript

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 44.44% year over year to ($0.10), which were in line with the estimate of ($0.10).

AcelRx Pharmaceuticals: Q4 Earnings Insights

REDWOOD CITY, Calif., March 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its fourth quarter and full year 2020 financial results.

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

REDWOOD CITY, Calif., March 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release fourth quarter financial results after market close on Monday, March 15, 2021. AcelRx management will host a live...

AcelRx to Host Fourth Quarter and Full Year 2020 Financial Results Call and Webcast on March 15, 2021

Will AcelRx Pharmaceuticals (ACRX) Report Negative Q4 Earnings? What You Should Know

It has been over two years since DSUVIA's approval, but AcelRx is finally starting to record some sales. The launch took longer than expected and the share price was punished. The Department of Defense is expected to receive ~$30M of DSUVIA in the coming years. The DoD contracts should bolster the early commercial numbers until the hospital numbers kick-in.

AcelRx Pharmaceuticals: Waiting For The Numbers To Close The Gap

The company announced the pricing of a public stock offering.

Why AcelRx Pharmaceuticals Stock Is Sinking Today

REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced an underwritten public...

AcelRx Announces Underwritten Public Offering of Common Stock

Investors need to pay close attention to AcelRx (ACRX) stock based on the movements in the options market lately.

News for AcelRx Pharmaceuticals Stock (ACRX)